Business
Revvity provides life-science tools, diagnostics, reagents, software and laboratory services.
Revvity delivered modest growth, higher profit and strong free cash flow, though cash conversion softened as the health-science portfolio evolved.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 3.7%OK
- Profitability — Net income declined 10.8% to $241.201M from $270.385MWatch
- Cash flow — Free cash flow declined 6.0% to $509.411M from $541.651MWatch
- Margins — Operating margin contracted 10 bps to 12.49%Watch
- Accounting — Health-science cash generation with softer conversionNote
- Insiders — 0 purchases and 7 salesNote
Where the revenue comes from
Fiscal 2025, as REVVITY, INC. reports it. History and quarterly detail are in the app.
- Life Sciences$1.4B
- Diagnostics$1.4B
Leadership changes
From REVVITY, INC.'s own filings, the day they're filed.
- Anita Gonzales · President · appointmenteff. 2025-10-23
- Controllership Initiatives · Director · appointment
- Sylvie Gr · member · departure
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-05-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about REVVITY, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.